Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Growth Hormone for Fatty Liver in Post-Surgery GHD
NCT06448195Phase 4Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jan 2023
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of genotropin miniquick in growth hormone deficiency (GHD) and non-alcoholic fatty liver disease (NAFLD) (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Percentage of liver fat at 6 months. Started Jan 2023; status: recruiting.
02
Drugs
genotropin miniquick
03
Conditions
growth hormone deficiency (GHD)non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT06448195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06448195.